Analysis of antibiotic consumption in the Czech Republic and its conclusions for clinical practice

Petr Domecký, Lenka Suchopárová, Josef Malý

Klin Farmakol Farm. 2021;35(3):49-55 | DOI: 10.36290/far.2021.017  

Introduction: Antibiotics (ATB) are essential medicines and have unquestionable uses. Unfortunately, the irrational use of ATB leads to the risks of adverse effects, interactions, and the development of drug resistance. This study aimed to analyse ATB consumption for systemic use in the Czech Republic (CR) in 2005-2019 and provide conclusions for clinical practice. Methods: The analysis of ATB consumption for systemic use was performed as a longitudinal retrospective analysis of data from the State Institute for Drug Control database in the years 2005-2019 using the standard methodology for studying drug consumption of the DUR (Drug Utilization Review)...

Cellular therapy with axicabtagene ciloleucel

František Folber, Marcela Cermanová, Jan M. Horáček, Tomáš Kupsa

Klin Farmakol Farm. 2021;35(3):56-60  

Patients with relapsed/refractory non-Hodgkin B-cell lymphomas suffer from a very poor survival. Chimeric antigen receptor T-cells (CAR-T) offer an attractive treatment approach using autologous genetically modified immune-effector cells. Main advantages include good treatment response, short-term and predictable toxicity profile, and prolonged survival. This review summarizes clinical trials with axicabtagene ciloleucel (axi-cel, Yescarta), published results, and real-world experience including first Czech data.

Current trends in treating acute myeloid leukaemia: from "7+3" induction chemotherapy to targeted therapy

Martin Čerňan, Tomáš Szotkowski

Klin Farmakol Farm. 2021;35(3):61-69  

Acute myeloid leukaemia is a cancer of haematopoietic cells, particularly affecting elderly patients. The "7+3" induction chemotherapy protocol, followed by consolidation therapy, has been the mainstay of curative treatment for several decades. The strategy for improving treatment outcomes has long been focused on combining and optimizing the doses of classic cytostatic drugs. The ongoing research allowing a better understanding of the biology of acute myeloid leukaemia and the pathways involved in the process of leukaemogenesis has discovered new potential therapeutic goals. Molecularly targeted therapy is a promising modern treatment method of acute...

Treatment of multiple myeloma in 2021

Jiří Minařík

Klin Farmakol Farm. 2021;35(3):70-77 | DOI: 10.36290/far.2021.020  

The treatment of multiple myeloma (MM) has evolved significantly in the recent years. The following are considered to be the major milestones which have led to a substantial improvement in prognosis: a shift of treatment to early (asymptomatic) disease stage, an emphasis on achieving negativity of minimal residual disease as well as the development of novel drugs with a biological mechanism of action. The novel drug classes used in the treatment of MM particularly include proteasome inhibitors (bortezomib, carfilzomib, ixazomib), immunomodulatory drugs (thalidomide, lenalidomide, pomalidomide), and monoclonal antibodies (daratumumab, elotuzumab, isatuximab)....

Drug interactions of antiepileptic drugs. Part 3: interaction with hormonal contraception

Blanka Kořístková, Milan Grundmann

Klin Farmakol Farm. 2021;35(3):78-79  

The metabolism of contraceptives is enhanced and thereby contraceptive failure might occur in combination with carbamazepine, eslicarbazepine, felbamate, phenobarbital, phenytoin, oxcarbazepine, perampanel, primidone, rufinamide or higher levels of topiramate. Estrogen component considerably declines lamotrigine level with the necessity to increase the dose. Lamotrigine concentrations consequently significantly increase during the hormonal contraceptive washout week and may be associated with intermittent lamotrigine-related toxicity. Lamotrigine produces a modest reduction in the progesterone level which might result in contraceptive failure in patients...

Nintedanib in treating interstitial lung disease associated with systemic scleroderma

Martina Šterclová

Klin Farmakol Farm. 2021;35(3):80-86 | DOI: 10.36290/far.2021.022  

Interstitial lung disease often accompanies systemic scleroderma and manifests itself in up to half of patients. It is also the most common cause of death in patients with systemic scleroderma. According to the literature, 8 % of patients with interstitial lung involvement due to systemic scleroderma should suffer from a progressive phenotype. Recent years have yielded the results of SENSCIS and INBUILD clinical trials, which demonstrated the effect of nintedanib in slowing the decline in forced vital capacity after one year of treatment in patients with interstitial lung disease due to systemic sclerosis and in patients with a progressive phenotype...

9. ČESKO­‑SLOVENSKÁ KONFERENCIA KLINICKEJ FARMAKOLÓGIE - ABSTRAKTA

Kolektiv autorů

Klin Farmakol Farm. 2021;35(3):87-95